Compugen Ltd (CGEN) 6.62 $CGEN
Compugen Finance Wins Sustainability Award From Toronto Region Board of Trade
Marketwire Canada - Thu Nov 13, 10:20AM CST
Compugen Finance is proud to have won the Toronto Region Board of Trade's 2014 Business Excellence award for Sustainability. The Award was presented at the Business Excellence Awards Ceremony at Toronto Don Valley Hotel on 6 November 2014.
CGEN: 6.62 (-0.21)
Shares of CGEN Down 15.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 12, 10:05AM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 1 month, Compugen has returned 15.74% as of today's recent price of $6.61.
CGEN: 6.62 (-0.21)
Compugen to Present at Jefferies 2014 Global Healthcare Conference in London
Business Wire - Wed Nov 12, 6:02AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.
CGEN: 6.62 (-0.21)
Should Compugen (CGEN) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:35AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Compugen, the stock of which company has actually seen rising estimates over the past one month.
CGEN: 6.62 (-0.21)
Compugen incurs higher net loss of USD5.4m for Q3 2014
M2 - Thu Oct 30, 6:13AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) stated on Wednesday its net loss of USD5.4m (USD0.11 per diluted share) for the third quarter ending 30 September 2014.
CGEN: 6.62 (-0.21)
Compugen's (CGEN) CEO Anat Cohen-Dayag on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 2:07PM CDT
CGEN: 6.62 (-0.21)
Compugen ups revenues 6% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:04PM CDT
CGEN: 6.62 (-0.21)
Compugen posts 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Wednesday reported a loss of $5.4 million, or 11 cents per share, in its third quarter.
CGEN: 6.62 (-0.21)
Compugen EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:17AM CDT
CGEN: 6.62 (-0.21)
Compugen Ltd. Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:13AM CDT
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the third quarter and nine months ending September 30, 2014.
CGEN: 6.62 (-0.21)
Betting On Big Data To Beat Aging
Ian C. Clift - Seeking Alpha - Tue Oct 28, 3:31PM CDT
Live forever or die rich -- betting on biotech stocks is like betting on life itself. But one given is that life ends, so is biotech a bad bet? Not if we can forestall death with better drugs and not if drug companies learn to use the giant boon in...
HLF: 37.85 (+0.04), GERN: 2.31 (-0.06), CGEN: 6.62 (-0.21), ABBV: 63.63 (-0.13), GOOG: 545.38 (-1.93), AAPL: 112.82 (+1.57), CELG: 107.43 (-0.82)
Compugen Discloses Successful Validation Results for Novel B7/CD28-like Cancer Immunotherapy Target Candidate
Business Wire - Mon Oct 27, 6:01AM CDT
--Compugen-discovered immune checkpoint candidates show potential for development of multiple cancer immunotherapies
CGEN: 6.62 (-0.21)
Compugen reports October 29
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:37AM CDT
CGEN: 6.62 (-0.21)
Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET
Business Wire - Wed Oct 22, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Wednesday, October 29, 2014 to review third quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
CGEN: 6.62 (-0.21)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.54 (+0.23), CGEN: 6.62 (-0.21), TEVA: 57.17 (-1.27), AMPE: 3.38 (+0.11), MNTA: 10.54 (-0.17), NVS: 94.38 (+1.72)
RTM Consulting to Present 'Consulting Soft Skills: Mission Critical for B4B Suppliers' at Technology Services World
Marketwired - Wed Oct 15, 9:11AM CDT
Cincinnati-based RTM Consulting, the leading provider of Resource Management solutions for consulting, professional and support services organizations in the IT sector, today announced they will co-present with the Technology Services Industry Association (TSIA) and RTM Consulting clients Compugen, Medidata Solutions and Ontario Systems at Technology Services World 2014 Service Transformations conference, taking place October 20 - 22 at the ARIA Resort in Las Vegas. The Technology Services World conference has become renowned as the preeminent source of learning and peer networking for technology services professionals.
MDSO: 42.41 (-0.64), CGEN: 6.62 (-0.21)
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Tue Oct 14, 1:02PM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced today relates to the second preclinical milestone for one of the checkpoint protein candidates. The achievement of the initial milestone for this candidate was announced in July of this year.
CGEN: 6.62 (-0.21)
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
Business Wire - Mon Oct 06, 6:08AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
CGEN: 6.62 (-0.21)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ACE: 110.65 (-0.12), COF: 81.60 (+0.03), CBK: 6.81 (-0.37), CGEN: 6.62 (-0.21), BPFH: 13.19 (-0.19)
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy
Business Wire - Wed Oct 01, 6:01AM CDT
--CGEN-15049 therapeutic antibody development is underway
CGEN: 6.62 (-0.21)
Compugen Finance Wins Sustainability Award From Toronto Region Board of Trade
Marketwire Canada - Thu Nov 13, 10:20AM CST
Compugen Finance is proud to have won the Toronto Region Board of Trade's 2014 Business Excellence award for Sustainability. The Award was presented at the Business Excellence Awards Ceremony at Toronto Don Valley Hotel on 6 November 2014.
CGEN: 6.62 (-0.21)
Shares of CGEN Down 15.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 12, 10:05AM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 1 month, Compugen has returned 15.74% as of today's recent price of $6.61.
CGEN: 6.62 (-0.21)
Compugen to Present at Jefferies 2014 Global Healthcare Conference in London
Business Wire - Wed Nov 12, 6:02AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.
CGEN: 6.62 (-0.21)
Should Compugen (CGEN) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:35AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Compugen, the stock of which company has actually seen rising estimates over the past one month.
CGEN: 6.62 (-0.21)
Compugen incurs higher net loss of USD5.4m for Q3 2014
M2 - Thu Oct 30, 6:13AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) stated on Wednesday its net loss of USD5.4m (USD0.11 per diluted share) for the third quarter ending 30 September 2014.
CGEN: 6.62 (-0.21)
Compugen's (CGEN) CEO Anat Cohen-Dayag on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 2:07PM CDT
CGEN: 6.62 (-0.21)
Compugen ups revenues 6% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:04PM CDT
CGEN: 6.62 (-0.21)
Compugen posts 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Wednesday reported a loss of $5.4 million, or 11 cents per share, in its third quarter.
CGEN: 6.62 (-0.21)
Compugen EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:17AM CDT
CGEN: 6.62 (-0.21)
Compugen Ltd. Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:13AM CDT
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the third quarter and nine months ending September 30, 2014.
CGEN: 6.62 (-0.21)
Betting On Big Data To Beat Aging
Ian C. Clift - Seeking Alpha - Tue Oct 28, 3:31PM CDT
Live forever or die rich -- betting on biotech stocks is like betting on life itself. But one given is that life ends, so is biotech a bad bet? Not if we can forestall death with better drugs and not if drug companies learn to use the giant boon in...
HLF: 37.85 (+0.04), GERN: 2.31 (-0.06), CGEN: 6.62 (-0.21), ABBV: 63.63 (-0.13), GOOG: 545.38 (-1.93), AAPL: 112.82 (+1.57), CELG: 107.43 (-0.82)
Compugen Discloses Successful Validation Results for Novel B7/CD28-like Cancer Immunotherapy Target Candidate
Business Wire - Mon Oct 27, 6:01AM CDT
--Compugen-discovered immune checkpoint candidates show potential for development of multiple cancer immunotherapies
CGEN: 6.62 (-0.21)
Compugen reports October 29
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:37AM CDT
CGEN: 6.62 (-0.21)
Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET
Business Wire - Wed Oct 22, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Wednesday, October 29, 2014 to review third quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
CGEN: 6.62 (-0.21)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.54 (+0.23), CGEN: 6.62 (-0.21), TEVA: 57.17 (-1.27), AMPE: 3.38 (+0.11), MNTA: 10.54 (-0.17), NVS: 94.38 (+1.72)
RTM Consulting to Present 'Consulting Soft Skills: Mission Critical for B4B Suppliers' at Technology Services World
Marketwired - Wed Oct 15, 9:11AM CDT
Cincinnati-based RTM Consulting, the leading provider of Resource Management solutions for consulting, professional and support services organizations in the IT sector, today announced they will co-present with the Technology Services Industry Association (TSIA) and RTM Consulting clients Compugen, Medidata Solutions and Ontario Systems at Technology Services World 2014 Service Transformations conference, taking place October 20 - 22 at the ARIA Resort in Las Vegas. The Technology Services World conference has become renowned as the preeminent source of learning and peer networking for technology services professionals.
MDSO: 42.41 (-0.64), CGEN: 6.62 (-0.21)
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Tue Oct 14, 1:02PM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced today relates to the second preclinical milestone for one of the checkpoint protein candidates. The achievement of the initial milestone for this candidate was announced in July of this year.
CGEN: 6.62 (-0.21)
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
Business Wire - Mon Oct 06, 6:08AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
CGEN: 6.62 (-0.21)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ACE: 110.65 (-0.12), COF: 81.60 (+0.03), CBK: 6.81 (-0.37), CGEN: 6.62 (-0.21), BPFH: 13.19 (-0.19)
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy
Business Wire - Wed Oct 01, 6:01AM CDT
--CGEN-15049 therapeutic antibody development is underway
CGEN: 6.62 (-0.21)
